Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab in Previously Treated AL Amyloidosis
NCT06935162Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of teclistamab in immunoglobulin light chain amyloidosis, sponsored by Peking Union Medical College Hospital. Started May 2025; status: recruiting.
02
Drugs
teclistamab
03
Conditions
immunoglobulin light chain amyloidosis
Beyond the preview
Go deeper on NCT06935162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06935162.